Ligand Pharmaceuticals Statistics
Total Valuation
LGNXZ has a market cap or net worth of 3.27 billion. The enterprise value is 3.03 billion.
Market Cap | 3.27B |
Enterprise Value | 3.03B |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
Earnings Date | Nov 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +5.60% |
Shares Change (QoQ) | +3.83% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 19.16M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 23.52 |
PS Ratio | 17.42 |
PB Ratio | 3.94 |
P/TBV Ratio | 6.85 |
P/FCF Ratio | 60.94 |
P/OCF Ratio | 59.03 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 237.00, with an EV/FCF ratio of 56.48.
EV / Earnings | -39.92 |
EV / Sales | 16.14 |
EV / EBITDA | 237.00 |
EV / EBIT | n/a |
EV / FCF | 56.48 |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 0.01.
Current Ratio | 5.45 |
Quick Ratio | 4.59 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.27 |
Debt / FCF | 0.11 |
Interest Coverage | -3.92 |
Financial Efficiency
Return on equity (ROE) is -9.46% and return on invested capital (ROIC) is -1.11%.
Return on Equity (ROE) | -9.46% |
Return on Assets (ROA) | -0.98% |
Return on Invested Capital (ROIC) | -1.11% |
Return on Capital Employed (ROCE) | -1.62% |
Revenue Per Employee | 2.76M |
Profits Per Employee | -1.12M |
Employee Count | 68 |
Asset Turnover | 0.21 |
Inventory Turnover | 4.67 |
Taxes
Income Tax | -8.63M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.50% in the last 52 weeks. The beta is 0.71, so LGNXZ's price volatility has been lower than the market average.
Beta (5Y) | 0.71 |
52-Week Price Change | -62.50% |
50-Day Moving Average | 0.00 |
200-Day Moving Average | 0.00 |
Relative Strength Index (RSI) | 42.20 |
Average Volume (20 Days) | 69,790 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 5.58 |
Income Statement
In the last 12 months, LGNXZ had revenue of 187.58 million and -75.86 million in losses. Loss per share was -4.00.
Revenue | 187.58M |
Gross Profit | 107.79M |
Operating Income | -14.30M |
Pretax Income | -84.50M |
Net Income | -75.86M |
EBITDA | 19.73M |
EBIT | -14.30M |
Loss Per Share | -4.00 |
Balance Sheet
The company has 245.02 million in cash and 5.74 million in debt, giving a net cash position of 239.28 million.
Cash & Cash Equivalents | 245.02M |
Total Debt | 5.74M |
Net Cash | 239.28M |
Net Cash Per Share | n/a |
Equity (Book Value) | 828.53M |
Book Value Per Share | 42.68 |
Working Capital | 288.21M |
Cash Flow
In the last 12 months, operating cash flow was 55.36 million and capital expenditures -1.74 million, giving a free cash flow of 53.62 million.
Operating Cash Flow | 55.36M |
Capital Expenditures | -1.74M |
Free Cash Flow | 53.62M |
FCF Per Share | n/a |
Margins
Gross margin is 57.46%, with operating and profit margins of -7.62% and -40.44%.
Gross Margin | 57.46% |
Operating Margin | -7.62% |
Pretax Margin | -45.04% |
Profit Margin | -40.44% |
EBITDA Margin | 10.52% |
EBIT Margin | -7.62% |
FCF Margin | 28.58% |
Dividends & Yields
LGNXZ does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.60% |
Shareholder Yield | n/a |
Earnings Yield | -2.32% |
FCF Yield | 1.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
LGNXZ has an Altman Z-Score of 11.36 and a Piotroski F-Score of 3.
Altman Z-Score | 11.36 |
Piotroski F-Score | 3 |